Previous 10 | Next 10 |
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a MISSION Phase 1b data update call for investors and analysts during the Eur...
Kezar Life Sciences (KZR): Q1 GAAP EPS of -$0.25 misses by $0.01.Cash, cash equivalents and marketable securities of $142.31M.Press Release For further details see: Kezar Life Sciences EPS misses by $0.01
KZR-616 clinical development in three severe autoimmune diseases is advancing with several data readouts expected in 2021 and 2022 KZR-261 IND submission expected mid-2021, with Phase 1 trial in solid tumors expected to initiate before year-end Cash, cash equivalents...
Kezar Life Sciences , Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, has been recognized as a winner of the 2021 Bay Area Best Places to Work , an awards program pres...
Kezar Life Sciences, Inc. (Nasdaq), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today presented preclinical data on the company’s novel protein secretion program during two poster sessions ...
An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...
Kezar Life Sciences (KZR): Non-GAAP EPS of -$0.22.Cash, cash equivalents and marketable securities totaled $140.4M as of December 31, 2020.Press Prelease For further details see: Kezar Life Sciences reports Q4 results
KZR-616 clinical development in three severe autoimmune diseases is advancing with several data readouts expected in 2021 and 2022, subject to developments in the ongoing COVID-19 pandemic. Upcoming poster presentations at AACR validate that inhibition of Sec61 with a small ...
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in the “Autoimmune/Complement&...
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the BIO CEO &...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...